Chris Schott
Stock Analyst at J.P. Morgan
(4.38)
# 1,275
Out of 5,000 analysts
623
Total ratings
57.9%
Success rate
6.3%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterated: Buy | $280 → $285 | $264.66 | +7.69% | 39 | Sep 25, 2026 | |
| PFE Pfizer | Reiterated: Hold | $28 | $28.57 | -2.00% | 91 | Sep 25, 2026 | |
| TLV: TEVA Teva Pharmaceutical Industries Limited | Reiterated: Buy | n/a | $12,050.00 | - | 1 | Sep 24, 2026 | |
| AMRX Amneal Pharmaceuticals | Reiterated: Buy | n/a | $19.80 | - | 21 | Sep 21, 2026 | |
| LLY Eli Lilly and Company | Reiterated: Buy | $1,400 | $1,185.00 | +18.14% | 73 | Sep 2, 2026 | |
| MRK Merck & Co. | Reiterated: Buy | n/a | $148.72 | - | 36 | Aug 19, 2026 | |
| ELAN Elanco Animal Health | Reiterated: Buy | n/a | $22.56 | - | 23 | Aug 11, 2026 | |
| RPRX Royalty Pharma | Reiterated: Buy | $58 → $62 | $58.25 | +6.44% | 10 | Aug 10, 2026 | |
| VTRS Viatris | Reiterated: Hold | $18 | $17.94 | +0.36% | 29 | Aug 10, 2026 | |
| ZTS Zoetis | Reiterated: Buy | $130 → $115 | $70.80 | +62.43% | 16 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $300 → $350 | $415.11 | -15.69% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $160 | $150.20 | +6.52% | 34 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $73 | $62.80 | +16.25% | 42 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $850 → $900 | $789.59 | +13.98% | 32 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $185 → $210 | $227.72 | -7.78% | 20 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $260 → $270 | $271.53 | -0.56% | 20 | Jul 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $15 | $15.45 | -2.91% | 31 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 → $11 | $13.74 | -19.94% | 13 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $675 → $775 | $518.49 | +49.47% | 15 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 → $8 | $1.14 | n/a | 9 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $8.06 | n/a | 41 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $2.06 | n/a | 3 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €84.40 → €86.15 | €135.00 | n/a | 2 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $43 → $54 | $25.20 | n/a | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.0001 | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $0.4701 | n/a | 3 | Nov 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $13.18 | n/a | 1 | Oct 17, 2013 |
AbbVie
Sep 25, 2026
Reiterated: Buy
Price Target: $280 → $285
Current: $264.66
Upside: +7.69%
Pfizer
Sep 25, 2026
Reiterated: Hold
Price Target: $28
Current: $28.57
Upside: -2.00%
Teva Pharmaceutical Industries Limited
Sep 24, 2026
Reiterated: Buy
Price Target: n/a
Current: $12,050.00
Upside: -
Amneal Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: n/a
Current: $19.80
Upside: -
Eli Lilly and Company
Sep 2, 2026
Reiterated: Buy
Price Target: $1,400
Current: $1,185.00
Upside: +18.14%
Merck & Co.
Aug 19, 2026
Reiterated: Buy
Price Target: n/a
Current: $148.72
Upside: -
Elanco Animal Health
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $22.56
Upside: -
Royalty Pharma
Aug 10, 2026
Reiterated: Buy
Price Target: $58 → $62
Current: $58.25
Upside: +6.44%
Viatris
Aug 10, 2026
Reiterated: Hold
Price Target: $18
Current: $17.94
Upside: +0.36%
Zoetis
Aug 10, 2026
Reiterated: Buy
Price Target: $130 → $115
Current: $70.80
Upside: +62.43%
Aug 6, 2026
Reiterated: Hold
Price Target: $300 → $350
Current: $415.11
Upside: -15.69%
Aug 6, 2026
Reiterated: Buy
Price Target: $160
Current: $150.20
Upside: +6.52%
Aug 4, 2026
Reiterated: Buy
Price Target: $73
Current: $62.80
Upside: +16.25%
Aug 4, 2026
Reiterated: Buy
Price Target: $850 → $900
Current: $789.59
Upside: +13.98%
Jul 30, 2026
Reiterated: Hold
Price Target: $185 → $210
Current: $227.72
Upside: -7.78%
Jul 16, 2026
Rated: Hold
Price Target: $260 → $270
Current: $271.53
Upside: -0.56%
Feb 27, 2026
Reiterated: Hold
Price Target: $18 → $15
Current: $15.45
Upside: -2.91%
Feb 13, 2026
Reiterated: Sell
Price Target: $12 → $11
Current: $13.74
Upside: -19.94%
Nov 3, 2025
Reiterated: Buy
Price Target: $675 → $775
Current: $518.49
Upside: +49.47%
May 25, 2023
Reiterated: Hold
Price Target: $9 → $8
Current: $1.14
Upside: n/a
Jul 28, 2022
Downgraded: Hold
Price Target: n/a
Current: $8.06
Upside: n/a
May 19, 2020
Downgraded: Hold
Price Target: n/a
Current: $2.06
Upside: n/a
Mar 9, 2020
Reiterated: Buy
Price Target: €84.40 → €86.15
Current: €135.00
Upside: n/a
Feb 20, 2020
Reiterated: Hold
Price Target: $43 → $54
Current: $25.20
Upside: n/a
May 13, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.0001
Upside: n/a
Nov 17, 2017
Reiterated: Buy
Price Target: $35
Current: $0.4701
Upside: n/a
Oct 17, 2013
Downgraded: Hold
Price Target: n/a
Current: $13.18
Upside: n/a